Use BAC water (not sterile water) and proper aseptic technique to minimize contamination risk
celles qui voient apparatre les premiers signes de lge et souhaitent agir en prvention
The level of professionalism, expertise, and attention to detail exceeded my expectations
End-of-Phase 2 FDA meeting Q2 2026GlobalType 2 diabetes mellitus with obesity/overweightPhase 2Enrolling (38-week study)Global ACCG-2671ACCG-2671 / Amylin/calcitonin receptor (DACRA) / Oral small molecule agonist / Metabolic / ObesityObesityPhase 1Active (SAD study initiated Dec 2025)Global ACCG-3535ACCG-3535 / Amylin/calcitonin receptor (DACRA) / Oral small molecule agonist / Metabolic / ObesityObesityPreclinical / IND-enablingPhase 1 initiation expected 2H 2026Global ANPA-0073ANPA-0073 / Apelin (APJ) receptor / Oral small molecule biased agonist / Metabolic / ObesityObesity (selective/muscle-sparing weight loss)Phase 2 readyPhase 1 SAD/MAD completedGlobal LTSE-2578LTSE-2578 / LPA1R (lysophosphatidic acid 1 receptor) / Oral small molecule antagonist / Pulmonary / FibrosisIdiopathic pulmonary fibrosis (IPF)Phase 1Phase 1 SAD/MAD completedGlobal GIPR ProgramGIPR (and GLP-1R/GIPR) / Oral small molecule (agonist/antagonist) / Metabolic / ObesityObesity and related diseasesDiscovery / PreclinicalActiveGlobal GCGR ProgramGCGR (and GLP-1R/GCGR) / Oral small molecule agonist / Metabolic / ObesityObesity and related diseasesDiscovery / PreclinicalActiveGlobal 7assets PitolisantWAKIX / histamine-3 receptor (H3R) antagonist/inverse agonist / small molecule / Rare neurological disordersPrader-Willi syndromePhase 3USNarcolepsy (GR formulation)Phase 3USNarcolepsy (HD formulation)Phase 3US BP1.15205orexin-2 receptor (OX2R) agonist / small molecule / Sleep/wake disordersNarcolepsy and other sleep/wake disordersPhase 1USLatin America EPX-1005-HT (serotonin) receptor agonist / small molecule / Rare epilepsiesDravet syndromePhase 3USLennox-Gastaut syndromePhase 3US EPX-200selective 5HT2C agonist / small molecule / Rare epilepsiesDevelopmental and epileptic encephalopathiesPreclinicalIND-enablingUS CBS-105cell therapy / Rare neurological disordersTreatment-resistant narcolepsyPreclinicalUS HBS-102MCHR1 antagonist / small molecule / Rare neurological disordersPrader-Willi syndromePreclinicalUS CBS-104cell therapy / Rare epilepsiesRefractory epilepsyPreclinicalUS 7assets 7assets LifileucelLN-144 / Amtagvi / Polyclonal Neoantigens / Tumor Infiltrating Lymphocyte (TIL) Therapy / OncologyMelanomaNon-Small Cell Lung Cancer (NSCLC) TIL CombinationsPolyclonal Neoantigens / Cell Therapy Combination / OncologySolid Tumors PD-1 Selected TILPolyclonal Neoantigens / PD-1+ / Tumor Infiltrating Lymphocyte (TIL) Therapy / OncologySolid Tumors Third Generation (Gen 3) TILPolyclonal Neoantigens / Tumor Infiltrating Lymphocyte (TIL) Therapy / OncologySolid Tumors PBL TherapyPolyclonal Neoantigens / Peripheral Blood Lymphocyte Therapy / OncologySolid Tumors PD-1 Inactivated TILIOV-4001 / PD-1 / Genetically Modified Cell Therapy / OncologySolid Tumors Modified IL-2 Fusion ProteinIOV-3001 / IL-2 Receptor / Antibody Cytokine Engrafted Protein / OncologyMelanomaSolid Tumors 7assets 7assets 7assets LX2006LX2006 / FXN / AAV gene therapy / CardiovascularFriedreich's ataxia (FA) cardiomyopathy LX2020LX2020 / PKP2 / AAV gene therapy / CardiovascularPKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM) LX2021LX2021 / Cx43 / AAV gene therapy / CardiovascularDSP (Desmoplakin) cardiomyopathyDilated cardiomyopathy LX2022LX2022 / TNNI3 / AAV gene therapy / CardiovascularHypertrophic cardiomyopathy (HCM) LX1001LX1001 / APOE2 / AAV gene therapy / NeurologyAPOE4-associated Alzheimer's disease LX1021LX1021 / Christchurch-modified APOE2 / AAV gene therapy / NeurologyAPOE4-associated Alzheimer's disease LX1020LX1020 / APOE2 / APOE4 (miRNA) / AAV gene therapy / NeurologyAPOE4-associated Alzheimer's disease 7assets insulin humanAfrezza / Insulin receptor / Recombinant Protein / EndocrineType 1 and Type 2 Diabetes MellitusMarketedApprovedUSBrazilPediatric Diabetes MellitusPhase 3OngoingUS treprostinilTyvaso DPI / Prostacyclin receptor / Small Molecule / Orphan Lung DiseasesPulmonary Arterial Hypertension (PAH)MarketedApprovedUSPulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)MarketedApprovedUS clofazimine inhalation suspensionMNKD-101 / Bacterial DNA / Mycobacterial growth / Small Molecule / Orphan Lung DiseasesNontuberculous Mycobacterial (NTM) Lung DiseasePhase 3DiscontinuedUS clofazimine DPIMNKD-102 / Bacterial DNA / Mycobacterial growth / Small Molecule / Orphan Lung DiseasesNontuberculous Mycobacterial (NTM) Lung DiseasePreclinicalActiveUS nintedanib DPIMNKD-201 / Tyrosine kinase / Small Molecule / Orphan Lung DiseasesIdiopathic Pulmonary Fibrosis (IPF)Phase 1CompletedUS dornase alfa DPIMNKD-301 / DNase I / Recombinant Protein / Orphan Lung DiseasesCystic FibrosisPreclinicalActiveUS FBM5712 DPIMNKD-501 / ALK-5 kinase / TGF-beta / Small Molecule / Orphan Lung DiseasesPulmonary FibrosisPreclinicalActiveUS 7assets SomatrogonhGH-CTP / NGENLA / Growth hormone receptor / Biologic / EndocrinologyGrowth Hormone Deficiency (Pediatric)ApprovedactiveUSEUJapanGlobalGrowth Hormone Deficiency (Adults)Phase 3activeGlobal Calcifediol extended-releaseRayaldee / Rayaldee / Vitamin D receptor / Small Molecule / NephrologySecondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (Hemodialysis)Phase 2activeUS MDX2004MDX2004 / CD3 x CD28 x 4-1BB / Multispecific Antibody / OncologyAdvanced CancersPhase 1/2aactiveUS MDX2003MDX2003 / T-cell engager / Multispecific Antibody / OncologyLymphomaPhase 1activeUS ModeX COVID-19 Multispecific AntibodySARS-CoV-2 / Multispecific Antibody / Infectious DiseaseCOVID-19PreclinicalactiveUS ModeX Influenza Multispecific AntibodyInfluenza virus / Multispecific Antibody / Infectious DiseaseInfluenzaPreclinicalactiveUS Oral GLP-2 AgonistGLP-2 / Peptide / GastroenterologyShort Bowel SyndromePreclinicalactiveGlobal 7assets 18F-PivalateRAD 101 / FASN (Fatty acid synthase) / Small Molecule Radiopharmaceutical / DiagnosticsBrain metastases from solid tumors (Imaging)Phase 2bEnrollingUS 177Lu-RAD202RAD 202 / HER2 / Nanobody Radiotherapeutic / OncologyHER2-positive advanced solid tumorsPhase 1ActiveUSGlobal 177Lu-RAD204RAD 204 / PD-L1 / Nanobody Radiotherapeutic / OncologyPD-L1 positive advanced solid tumorsPhase 1ActiveUSGlobal 68Ga-TrivehexinRAD 301 / v6-integrin / Peptide Radiopharmaceutical / DiagnosticsLoco-regional pancreatic cancer (Imaging)Phase 2ActiveGlobal 177Lu-D0301RAD 302 / v6-integrin / Peptide Radiotherapeutic / OncologySolid tumors (PDAC, NSCLC, HNSCC)PreclinicalActiveGlobal BetaBartRV-01 / B7-H3 / Radiotherapeutic / OncologyB7H3-expressing solid tumorsPhase 1/2aActiveUS 161Tb-RAD 402RAD 402 / KLK3 (PSA) / Monoclonal Antibody Radiotherapeutic / OncologyAdvanced prostate cancerPhase 1ActiveAustralia 7assets SGT-003SGT-003 / Gene Therapy / NeuromuscularDuchenne muscular dystrophy (INSPIRE)Phase 1/2ActiveGlobalDuchenne muscular dystrophy (IMPACT)Phase 3Activeex-U.S
The HFD model mimics steatosis resulting from excessive fat intake (Li et al., 2024), while the HFrD model recapitulates impairments from high-sugar diets (Sapp et al., 2014)
However, the evidence for oral glutathione absorption remains limited
